Tango Therapeutics Inc
Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant … Read more
Tango Therapeutics Inc (TNGX) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.193x
Based on the latest financial reports, Tango Therapeutics Inc (TNGX) has a cash flow conversion efficiency ratio of -0.193x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-30.95 Million) by net assets ($160.03 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Tango Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how Tango Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Tango Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Tango Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Sumber Alfaria Trijaya Tbk
JK:AMRT
|
0.049x |
|
Ito En Ltd
PINK:ITOEF
|
0.026x |
|
Montea C.V.A.
BR:MONT
|
0.008x |
|
Kyushu Railway Company
OTCGREY:KYHHY
|
N/A |
|
Novoray Corporation
SHG:688300
|
0.057x |
|
Six Flags Entertainment Corporation
NYSE:FUN
|
0.413x |
|
EZAKI GLICO
F:5EJ
|
N/A |
|
Anhui Great Wall Military Industry Co Ltd
SHG:601606
|
-0.010x |
Annual Cash Flow Conversion Efficiency for Tango Therapeutics Inc (2019–2024)
The table below shows the annual cash flow conversion efficiency of Tango Therapeutics Inc from 2019 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $199.52 Million | $-131.50 Million | -0.659x | -41.40% |
| 2023-12-31 | $253.11 Million | $-117.98 Million | -0.466x | -6.61% |
| 2022-12-31 | $249.48 Million | $-109.08 Million | -0.437x | -153.22% |
| 2021-12-31 | $344.75 Million | $-59.53 Million | -0.173x | -109.51% |
| 2020-12-31 | $38.60 Million | $70.07 Million | 1.815x | +157.86% |
| 2019-12-31 | $7.91 Million | $-24.80 Million | -3.138x | -- |